These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19555308)

  • 1. In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.
    Skidan I; Miao B; Thekkedath RV; Dholakia P; Degterev A; Torchilin V
    Drug Deliv; 2009 Jan; 16(1):45-51. PubMed ID: 19555308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo.
    Riehle RD; Cornea S; Degterev A; Torchilin V
    Drug Deliv; 2013 Feb; 20(2):78-85. PubMed ID: 23495715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
    Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
    Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.
    Skidan I; Grunwald J; Thekkedath R; Degterev A; Torchilin V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1610-6. PubMed ID: 21514904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone.
    Grandhi TS; Potta T; Taylor DJ; Tian Y; Johnson RH; Meldrum DR; Rege K
    Nanomedicine (Lond); 2014; 9(12):1775-88. PubMed ID: 24195660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy.
    Feng C; Han X; Chi L; Sun J; Gong F; Shen Y
    J Biomater Sci Polym Ed; 2018 Oct; 29(14):1729-1744. PubMed ID: 29851539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis.
    Zhang Z; Patel SB; King MR
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
    Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
    Drug Deliv; 2012 May; 19(4):169-76. PubMed ID: 22506922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
    Skidan I; Dholakia P; Torchilin V
    J Drug Target; 2008 Jul; 16(6):486-93. PubMed ID: 18604661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.
    Wei X; Yang X; Zhao W; Xu Y; Pan L; Chen S
    Bioconjug Chem; 2017 Aug; 28(8):2180-2189. PubMed ID: 28697305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
    Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
    J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
    Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
    Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.
    Sawant RR; Sawant RM; Torchilin VP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):51-7. PubMed ID: 18583114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG).
    Chandran T; Katragadda U; Teng Q; Tan C
    Int J Pharm; 2010 Jun; 392(1-2):170-7. PubMed ID: 20363305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional Micellar Nanocarriers for Tumor-Targeted Delivery of Hydrophobic Drugs.
    Dai Z; Tu Y; Zhu L
    J Biomed Nanotechnol; 2016 Jun; 12(6):1199-210. PubMed ID: 27319214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
    De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
    Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing.
    Gao Z; Lukyanov AN; Chakilam AR; Torchilin VP
    J Drug Target; 2003 Feb; 11(2):87-92. PubMed ID: 12881194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
    Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
    Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.